ATHERSYS INC (ATHX)       0.6088  -0.03 (-4.13%)

0.6088  -0.03 (-4.13%)

US04744L2051 - Common Stock - After market: 0.6078 0 (-0.16%)


Fundamental Rating

2

Taking everything into account, ATHX scores 2 out of 10 in our fundamental rating. ATHX was compared to 635 industry peers in the Biotechnology industry. Both the profitability and financial health of ATHX have multiple concerns. ATHX shows excellent growth, but is valued quite expensive already.




Profitability

Profitability Rating

1

The profitability ratios for ATHX are negative, so there is not much use analyzing them.
ATHX has a Return On Assets of -228.58%. This is below the industry average of -44.83%. 96% of the industry peers outperform ATHX.

ATHX's Profit Margin of -1350.69% is worse than the rest of the industry. The industry average Profit Margin is -464.10%.
The Piotroski-F score of ATHX is 3.00. This is a low score and indicates issues in the health and profitability of ATHX.
VS Industry

ROA (-228.58%) VS Industry: 4% outperformed.

-3,944.82
115.38

Profit Margin (-1350.69%) VS Industry: 31% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

2

When comparing the Enterprise Value to EBITDA ratio of ATHX to the average industry ratio of 1.08, ATHX is valued rather cheaply. ATHX is also cheaper than 96% of the companies listed in the same industry.
The Price/Earnings Ratio is negative for ATHX. In the last year negative earnings were reported.

Also next year ATHX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Enterprise Value/ EBITDA (0.04) VS Industry: 96% outperformed.

3,199.01
0.01

Growth

Growth Rating

7

ATHX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.93%, which is quite impressive.
ATHX is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 14.13% yearly.
Based on estimates for the next 5 years, ATHX will show a very strong growth in Revenue. The Revenue will grow by 235.41% on average per year.

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Revenue has decreased by -0.78% in the past year.
Measured over the past 5 years, ATHX shows a very negative growth in Revenue. The Revenue has been decreasing by -20.49% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 22.93% 12.75% 4.2% 25.35% 14.13%
Revenue-20.49% -39% -0.78% -18.28% -5.21% 148.19% 235.41%

Health

Health Rating

1

The Debt to Equity ratio of ATHX is in line with the industry averages.
ATHX has a Current Ratio of 0.54. This is a bad value and indicates that ATHX is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.11, ATHX is worse placed to pay its short term obligations than its industry peers. 97% of its industry peers have a better Current Ratio.
ATHX has a Quick Ratio of 0.54. This is a bad value and indicates that ATHX is not financially healthy enough and could expect problems in meeting its short term obligations.

When comparing the Quick Ratio of ATHX to the average industry Current Ratio of 6.02, ATHX is less able to pay its short term obligations than its industry peers. 97% of its industry peers have a better Quick Ratio.
ATHX has an Altman-Z score of -33.03. This is a bad value and indicates that ATHX is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of ATHX to the average industry Altman-Z score of -0.65, ATHX is less financially healthy than its industry peers. 97% of its industry peers have a better Altman-Z score.
ATHX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ATHX.
VS Industry

Debt/Equity (0) VS Industry: 41% outperformed.

15.37
0.00

Quick Ratio (0.54) VS Industry: 3% outperformed.

0.02
84.53

Current Ratio (0.54) VS Industry: 3% outperformed.

0.02
85.09

Altman-Z (-33.03) VS Industry: 3% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

No dividends for ATHX!.

ATHX Daily chart

ATHERSYS INC0.6088

NASDAQ:ATHX (12/5/2022, 7:20:34 PM)-0.03 (-4.13%)

After market: 0.6078 0 (-0.16%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 03-13 2023-03-13
Ins Owners 10.52% Inst Owners 5.18%
Market Cap 10.59M Analysts 40
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 1.76 P/B N/A
EV/EBITDA 0.04
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 22.93% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 34.29%
EPS Next Y 12.75% EPS Next 2Y 4.2%
EPS Next 3Y 25.35% EPS Next 5Y 14.13%
Revenue growth 1Y -0.78% Revenue growth 3Y -39%
Revenue growth 5Y -20.49% Revenue growth Q2Q -98.64%
Revenue Next Year -18.28% Revenue Next 2Y -5.21%
Revenue Next 3Y 148.19% Revenue Next 5Y 235.41%
Health
Current Ratio 0.54 Quick Ratio 0.54
Altman-Z -33.03 F-Score 3
Debt/Equity 0 WACC 8.94%
ROIC/WACC N/A
Profitability
ROA -228.58% ROE N/A
ROICexgc N/A ROIC N/A
PM -1350.69% OM -1323.76%
Asset Turnover 0.17

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA